



# BMJ Open Evaluation of the design, conduct and reporting of randomised controlled trials in the haemodialysis population: a scoping review and interview study

Prachi Kaushal <sup>1</sup>, Sherna F Adenwalla,<sup>1,2</sup> Courtney J Lightfoot,<sup>3</sup> Daniel S March,<sup>1,4</sup> Laura J Gray,<sup>3</sup> James O Burton <sup>1,2</sup>

**To cite:** Kaushal P, Adenwalla SF, Lightfoot CJ, *et al*. Evaluation of the design, conduct and reporting of randomised controlled trials in the haemodialysis population: a scoping review and interview study. *BMJ Open* 2022;**12**:e058368. doi:10.1136/bmjopen-2021-058368

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2021-058368>).

PK and SFA are joint first authors.

Received 17 October 2021  
Accepted 24 February 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

<sup>1</sup>Department of Cardiovascular Sciences, University of Leicester, Leicester, UK

<sup>2</sup>John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK

<sup>3</sup>Department of Health Sciences, University of Leicester, Leicester, UK

<sup>4</sup>National Institute for Health Research Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK

## Correspondence to

Professor James O Burton;  
jb343@le.ac.uk

## ABSTRACT

**Background** Fewer trials are conducted in nephrology than any other specialty, often failing to recruit to target, resulting in unclear evidence affecting translation to clinical practice. This mixed-methods study aims to provide guidance for designing and reporting future randomised controlled trials (RCTs) in the haemodialysis population.

**Method** A scoping review was conducted. Five databases (MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov) were searched for RCTs published between 2013 and 2019 involving prevalent adult haemodialysis patients. Reporting of sample size, recruitment, retention and statistical significance of primary outcome were assessed. Face-to-face semistructured interviews were conducted with individuals from a single centre during dialysis sessions. Interviews were analysed thematically.

**Results** Of 786 RCTs identified, 636 (80.9%) were parallel-group, 139 (17.7%) were crossover and 11 (1.4%) were cluster (including one stepped-wedge) design. Sample size justification was reported in 73.1%, 53.8% and 45.5% of parallel-group, crossover and cluster trials, respectively.

Target recruitment was achieved by 45.5% of cluster, 53.8% of crossover and 57.7% of parallel-group trials with patient retention at 75.6%, 83.1% and 87.8%, respectively. Primary outcome reached statistical significance in 81.8% of cluster trials, 69.2% of parallel-group and 38.5% of crossover trials.

Themes identified from individual interviews: perceptions of the convenience of trial participation; group allocation; perceptions of the benefits and adverse effects of taking part in clinical trials.

**Conclusion** The recruitment and reporting of RCTs involving people on haemodialysis could be improved. Involvement of all stakeholders and especially participants in the trial design process may address issues around participant burden and ultimately improve the evidence base for clinical practice.

## INTRODUCTION

Nephrology has one of the lowest numbers of published randomised controlled trials

## Strengths and limitations of this study

- This scoping review includes a comprehensive collection of trials in the haemodialysis population over a 7-year period and is the first to assess by trial design.
- Semistructured interviews with individuals on dialysis complemented the review by identifying attitudes and perspectives to taking part in clinical trials.
- Not all parallel-group or crossover trials were included for review, but selection bias was reduced by using a random number generator.
- The interview size sample size was small, although purposive sampling was used to obtain a broad range of perspectives.
- The integration and synthesis of findings from the scoping review and interviews allows guidance to be suggested for future designing and reporting of clinical trials involving patients on haemodialysis.

(RCTs) across all medical specialties.<sup>1–3</sup> Furthermore, there has been no significant growth in the number of RCTs and compared with other specialties, the outcomes of these trials have had less impact in clinical practice.<sup>2–4</sup>

Inappropriate trial design, poor participant recruitment and retention, and inadequate reporting of trials have been identified as factors that can adversely affect trial outcomes.<sup>5–6</sup> Recent studies show poor reporting in nephrology trials,<sup>2–7–8</sup> despite the presence of Consolidated Standards of Reporting Trials (CONSORT) guidelines.<sup>9</sup> This is a particular problem when the number of RCTs performed is low (such as in nephrology) as each published trial has a greater contribution to the overall evidence base.<sup>8</sup> This led to the International Society of Nephrology (ISN) in 2016 identifying the need to increase the quality and quantity of trials in chronic kidney disease (CKD) by promoting conduct of clinical

trials, optimising trial design and increasing capacity for conducting trials.<sup>10</sup> One approach involves developing and using innovative trial designs.<sup>11</sup>

Previous qualitative studies exploring recruitment and retention in nephrology trials identified lack of knowledge, stress from participation, and feeling disconnected from the process affected participation.<sup>12</sup> Perceptions of RCT participation in the UK haemodialysis (HD) population requires further investigation to address barriers to participation and to shape future RCT design and implementation. The aim of this study was to explore how different trial designs can affect recruitment, retention and reporting of trials. We also sought the participant perspective on trial design and participation; these are priorities to address the need for more effective trials and in turn, to improve patient care.

## METHODS

### Study design

A mixed-methods study was conducted consisting of a scoping review and semistructured interviews. Due to the paucity of information currently published on this subject, a scoping review was chosen to allow a broad range of literature to be assessed using a systematic method.<sup>13–15</sup> We refer to non-standard trials as: cluster randomised parallel-group, crossover and stepped-wedge trials. The scoping review was complemented by semistructured interviews with people on maintenance HD to obtain participant attitudes and perspectives to taking part in clinical trials with a focus on recruitment and retention.

### Methods of scoping review

Details of the scoping review protocol are available elsewhere.<sup>16</sup>

### Eligibility criteria

Completed RCTs published between 2013 and 2019 were included, provided the trial design was one of the following: individually randomised parallel-group, crossover, cluster randomised parallel-group or stepped-wedge design. This period was chosen as the first stepped-wedge trial in patients with HD was published in 2013. Participants in the trials must have received HD for >3 months and be 18 years and older. All trials with any intervention, comparison and outcome were included. Publications solely of secondary and post hoc analyses were excluded.

### Search strategy

Five databases were searched: MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov. The last search date was 8 October 2019.

No limits on language were set to reduce language bias. An example of a full search strategy for the MEDLINE database is shown in table A-1 (online supplemental text, Appendix 1).

### Selection of sources of evidence

Search results were compiled using EndNote X9 and duplicate citations were removed.

Titles and abstracts were screened initially to assess eligibility by two reviewers (PK and DSM). If there was discrepancy or uncertainty from the initial screening, a third independent reviewer assessed titles and abstracts (JOB). If the abstract was unclear, the full text was accessed to understand the trial design.

Trials were categorised by design (ie, parallel group, cluster, crossover and stepped wedge). A sample of trials were selected using a random number generator, allowing for stratified sampling by design. Based on current literature, we expected cluster trials to be a small proportion of the total<sup>17</sup>; the number of cluster trials was therefore used to determine the numbers of other trials assessed. An equal number of crossover trials were assessed, and twice the number of parallel-group trials to account for the larger number of trials.

Publications within each trial design category were further subdivided by intervention type: 'Pharmacological' which included drug trials; 'Device' which included interventions such as choice of dialyzers; 'Procedure' involving interventions such as surgical procedures or changes in dialysis delivery; 'Lifestyle' consisted of dietary and exercise interventions and 'Other'. 'Other' consisted of 'Alternative Therapies' (Alt.), 'Psychological, behavioural and educational' (PBE) and a third 'Unclassified' subcategory. If a study compared two different intervention types, these were recorded twice.

The full text was only assessed to determine eligibility if the abstract was unclear.

### Data collection process and data items

Data extraction was carried out independently by one reviewer (PK) and verified by the second reviewer (DSM). The full data extraction items can be found in the online supplemental text, Appendix 2. Authors of papers were not contacted for missing data, as one of the objectives of this review was to assess the reporting of trials.

CONSORT extensions for crossover trials and cluster trials were used to identify data items specific to sample size reporting (item 7a on the CONSORT checklist).<sup>18 19</sup>

### Summary measures and synthesis of results

Papers were grouped according to trial design. Measures assessing reporting, achievement of target recruitment and achievement of significant primary end point were binary (Yes/No), summarised as raw numbers and percentages. Length of trial, number of participants recruited and number of finished trials were continuous outcomes, with the median and IQR calculated within the trial design category. Patient retention and attrition were calculated as percentages and the median percentage and IQR presented.

Data were synthesised using Microsoft Excel 16 and analysed using Stata 16 (Stata, College Station, Texas, USA).

## Methods of interviews

### Study design and participants

A pragmatic qualitative study was conducted using semi-structured interviews. Patients were recruited from a single dialysis unit in Leicester.

Inclusion criteria were the following: aged 18 years and older, on maintenance HD and ability to provide written informed consent. Participants were excluded if they were a hospital inpatient or if there was a language barrier. The aim was to recruit 10 participants; this sample size was chosen to reflect sufficiently diverse views and experiences within the time and resources available. Maximum variation purposive sampling was used to ensure a representative population reflecting differences in gender, ethnicity, age and previous research experience. Those who were screened as eligible to be interviewed were approached during their dialysis session and provided information about the study. Interviews were conducted the following week after being approached, at the same dialysis slot, and written informed consent was obtained prior to interview.

Ethics and research approval was obtained from the London-Surrey Border NHS Research Ethics Committee (REC ref: 19/LO/1816).

### Patient and public involvement

A patient and public involvement (PPI) meeting was held prior to interviews to ascertain general perspectives on taking part in clinical trials. Participants helped shape the interview topic guide and identified important themes and concepts to explore further during interviews (online supplemental text, Appendix 3). The method of undertaking interviews during dialysis was also explored. This meeting was held via Microsoft Teams in October 2020.

Following the PPI meeting, changes including increased use of lay terminology when referring to types of study design and further exploration of group assignment (intervention vs control) were made, as well as opting for interviews while on dialysis as this was highly favoured by the PPI group. Visual aids were used to provide further explanation of the different trial designs discussed (online supplemental text, Appendix 4).

### Interview procedure

Data were collected via semistructured interviews conducted face-to-face on the dialysis unit.

Interviews were conducted and audio-recorded by one of two researchers (PK and SFA) between November and December 2020. Researchers kept a reflexivity diary and field notes throughout the interview process. The researchers PK and SFA are clinicians, but not involved in the care of the participants, while CJL is a non-clinical researcher.

### Data analysis

All interviews were anonymised and transcribed verbatim by the same researcher who conducted the interview. QSR International NVivo12 was used to manage the data, which were analysed thematically using the principles outlined by

Braun and Clarke.<sup>20</sup> One researcher (PK) read the complete data set and independently identified codes. A sample of interviews were read and coded independently by a second researcher (SFA). Both researchers reviewed and agreed on the final codes. Patterns in the codes were identified and collated, from which themes were developed inductively. Themes were reviewed and agreed by PK and CJL.

## RESULTS

### Results of scoping review

#### Selection of trials

The process of identification and selection of papers included in this review, as well as reasons for exclusion, is depicted by [figure 1](#).

A total of 786 RCTs were identified in the prevalent HD population from 2013 to 2019. Six hundred and thirty-six (80.9%) were individually randomised parallel-group trials, 139 (17.7%) were crossover trials, 10 (1.3%) were cluster trials and 1 (0.1%) was a stepped-wedge trial. The stepped-wedge trial was also cluster randomised and therefore was included with cluster trials for analysis. In total, 50 trials were analysed for this scoping review.

Thirteen cluster trials, 13 crossover trials and 26 parallel-group trials were selected, the latter reflecting the larger proportion of parallel-group trials in total. Three cluster trials were excluded during data extraction (for reasons, see [figure 1](#)), resulting in 10 cluster trials. Trials included, organised by design, are presented in online supplemental text, Appendix 5.

#### Characteristics of trials

##### Characteristics of all trials

All trials were categorised according to their intervention type as shown in [table 1](#).

##### Characteristics of included trials


Cluster trials had the longest median duration (28 months, IQR: 12–39), followed by parallel-group trials (12 months, IQR: 5–25) and crossover trials (8 months, IQR: 6–12) ([table 2](#)). The duration of study was not consistently reported. Fourteen (53.8%) parallel-group and seven (53.8%) crossover trials reported the length of study, whereas only three (27.3%) cluster trials reported this ([table 2](#)).

The median number of participants recruited for cluster trials was 119 (IQR 90–259), 61 (IQR 45–100) for parallel-group trials and 33 (IQR 12–35) for crossover trials ([table 2](#)).

#### Reporting

##### Factors related to sample size

Sample size justification was provided in 19 (73.1%) parallel-group trials, compared with 7 (53.8%) crossover and 5 (45.5%) cluster trials ([table 2](#)). [Table 3](#) shows the additional CONSORT requirements for crossover and cluster trials, which were poorly reported; one (7.7%) crossover trial and no cluster trials fulfilled all the requirements. Of the five additional items that cluster trials should report regarding sample size, cluster size was



<sup>a</sup> Trial was stepped-wedge and cluster randomised

<sup>b</sup> Percentages calculated from final number of trials = 786 (following exclusion of 3 cluster trials)

**Figure 1** PRISMA flow diagram illustrating process of study identification and inclusion. HD, haemodialysis; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RCT, randomised controlled trial.

reported by two (18%) papers. The number of clusters in the sample size calculation and intracluster correlation coefficient (ICC) were reported by one (9%) paper. The two other parameters, assumption of equal or unequal cluster sizes and uncertainty in ICC, were unreported by all papers (table 2).

### Other factors

Use of a CONSORT flow diagram to represent participant flow was seen in 9 (81.8%) cluster trials, 21 (80.8%) parallel-group trials and 9 (69.2%) crossover trials. Target recruitment numbers were not reported in six (46.2%) crossover trials and three (27.3%) cluster and seven (26.9%) parallel-group trials.



**Table 1** Table showing trial design and intervention type of all trials

Characteristic	n	%
Trial design		
Individually randomised parallel group	636	80.9
Crossover	139	17.7
Cluster	10	1.3
Stepped wedge	1	0.1
Intervention type		
Pharmacological	290	36.9
Device	83	10.6
Procedure	58	7.4
Lifestyle	209	26.6
Other	149	19.0

'Pharmacological' included drug trials. 'Device' included interventions such as choice of dialysers. 'Procedure' involved interventions such as surgical procedures and changes in dialysis delivery (ie, high flow rate, temperature of dialysate). 'Lifestyle' consisted of dietary and exercise interventions. 'Other' consisted of trials that did not fit in any other category. This was further subdivided to include 'Alternative', such as acupuncture or music therapies which consisted of 74 trials and 'Psychological, Behavioural and Educational' which consisted of 43 trials. Some trials within 'other' did not fit any category and therefore remained 'Unclassified' which consisted of 32 trials. 'Unclassified' included interventions such as use of advanced care plans, nurse-led follow-ups or interventions and use of collaborative care models. If a study compared two different intervention types, these were recorded twice. Thus, the number of interventions is greater than the number of studies.

### Recruitment and retention

Fifteen (57.7%) parallel-group trials achieved their target recruitment, the highest percentage of trials assessed, followed by seven (53.8%) crossover trials and five (45.5%) cluster trials. The median patient retention in parallel-group trials was 87.8% (IQR 79.5%–95.4%), 83.1% (IQR 74.3%–91.7%) in crossover trials and 75.6% (IQR 65.9%–84.4%) in cluster trials.

Two cluster trials (18.2%) used the HD centre as the cluster, with the remaining nine (81.8%) trials using dialysis shift for the cluster.

### Trial outcomes

Cluster trials had the largest number achieving a statistically significant ( $p < 0.05$ ) primary outcome,  $n = 9$  (81.8%). Parallel-group trials had 18 (69.2%) and crossover trials had 5 (38.5%) achieving a statistically significant primary outcome.

### Interview findings

Thirteen potential participants were invited to be interviewed. Of those, 10 participants agreed and consented to be interviewed (figure 2). Participant characteristics are shown in table 4. On average, interviews were 31 min (IQR: 30–33).

**Table 2** Summary of data by trial designs

Trial designs	No of studies assessed	States how sample size was determined? % (n)	All sample size requirements reported? % (n)	Did not state target recruitment % (n)	Use of CONSORT flow diagram? % (n)	Stated length of trial? % (n)	Length of trial, median months (IQR)	Number recruited, median number (IQR)	No of finished trial, median number (IQR)	Achieved target recruitment? % (n)	Patient retention, median % (IQR)	Studies achieving >80% retention? % (n)	% Lost to follow-up due to withdrawal of consent, median % (IQR)	Achieved significant primary end point? % (n)
Parallel group	26	73.1 (19)	–	26.9 (7)	80.8 (21)	53.8 (14)	12 (5–25)	61 (45–100)	55.5 (38.5–81)	57.7 (15)	87.8 (79.5–95.4)	65.4 (17)	0 (0–34)	69.2 (18)
Crossover	13	53.8 (7)	7.7 (1)	46.2 (6)	69.2 (9)	53.8 (7)	8 (6–12)	33 (12–35)	24 (11–30)	53.8 (7)	83.1 (74.3–91.7)	69.2 (9)	0 (0–75)	38.5 (5)
Cluster	11	45.5 (5)	0	27.3 (3)	81.8 (9)	27.3 (3)	28 (12–39)	119 (90–259)	87 (60–186)	45.5 (5)	75.6 (65.9–84.4)	45.5 (5)	22.7 (11.4–28.6)	81.8 (9)

CONSORT, Consolidated Standards of Reporting Trials; IQR, Interquartile range; n, number of trials.

**Table 3** Reporting of crossover and cluster trials compared to CONSORT 2010 requirements

Trial design	No of studies assessed	States how sample size was determined? % (n)	States no of clusters in sample size calculation? % (n)	States cluster size? % (n)	States if equal or unequal cluster sizes are assumed? % (n)	States the ICC? % (n)	States uncertainty in ICC? % (n)	Within participant variability accounted for? % (n)
Crossover	13	53.8 (7)	N/A	N/A	N/A	N/A	N/A	7.69 (1)
Cluster	11	45.5 (5)	9.1 (1)	18.2 (2)	0	9.1 (1)	0	N/A

CONSORT, Consolidated Standards of Reporting Trials; ICC, intracluster correlation coefficient; n, number of trials; N/A, not applicable.

### Theme 1: perceptions of the convenience of trial participation

Exemplar quotes are displayed in [table 5](#).

#### Trial duration

Participants reported the ideal length of a trial was between a month and 18 months. A longer trial was considered acceptable if details about the trial were adequately explained, as participants acknowledged that kidney disease is a chronic condition thus longer trials maybe required. The length of the trial was not an issue to some participants as they felt they had ‘all the time on dialysis’. Others felt that a long duration could be time-consuming and burdensome depending on the necessary involvement, consequently leading them to decline or dropout. Acceptability and burden of the intervention or follow-up were considered to more likely impact participants’ adherence to the trial, including dropping out, than the duration and design of the trial.

#### Study visits

Most participants explained how they preferred trial visits to take place while they were receiving dialysis as it ‘helps pass the time’ or prior to their dialysis timeslot due to

‘little enough free time now’. One participant stated that if visits took place during dialysis, they may drop out if they felt unwell postdialysis.

### Theme 2: perceptions of equipoise

Exemplar quotes are displayed in [table 6](#).


Clinical equipoise is the necessary belief that neither the intervention nor the control is ‘better’ during the design of an RCT. In our interviews, the intervention group was perceived to be the most desirable group, with participants describing feeling more involved in the study and gaining potential health improvements. Participants felt that they would not benefit from the study if assigned to the control group; one participant explained that they would only continue to take part in a trial if they received the intervention. Conversely, a small number perceived the control group as ‘a contribution to the study, without the adverse risks’, and thus a preferable option.

Parallel-group trials were believed to be fair and recognised as the ‘standard way’ trials are conducted. The concept of stepped-wedge and crossover trials were generally well received by participants as they liked the idea of being guaranteed the intervention at some point, even if initially allocated to the control group.

### Theme 3: perceptions of the benefits and adverse effects of trial participation

Exemplar quotes are displayed in [table 7](#).

Most participants perceived clinical trials to provide greater benefit to future patients rather than those participating in the trial. Motivating factors to participate in trials were discussed which included being able to continue with an intervention long term, feeling part of a community, a sense of pride or feeling they are ‘giving back’. Some participants felt taking part in a cluster trial with others would be more motivating, with one participant reporting that talking to other participants would make him feel stronger. Participants believed having a personalised approach during the trial processes, such as having a good rapport with researchers, social events and newsletters, encouraged continued involvement. Participants who did not feel that they would benefit or who did not receive feedback reported being less likely to take part.



**Figure 2** Flow diagram representing participant recruitment for semistructured interviews.

**Table 4** Demographics of the participants Interviewed

Interview cohort (n=10)	Sex (M/F)	Age range (years)	Race	Dialysis vintage range (years)	Previous trial experience	
					Y/N	Trial design
P01	F	40–59	South Asian	5–10	Y	Parallel group
P02	F	>80	White	<5	N	
P03	M	60–79	White	<5	N	
P04	M	60–79	White	<5	Y	Parallel group
P05	M	>80	White	<5	N	
P06	M	20–39	South Asian	5–10	Y	Cluster
P07	F	40–59	White	<5	Y	Parallel group
P08	M	40–59	South Asian	<5	N	
P09	F	40–59	Mixed race	>10	Y	Parallel group, cluster
P10	M	60–79	Black	>10	Y	Parallel group, cluster

M, male; F, female; Y, yes; N, no

The adverse effects of participating in clinical trials were acknowledged, with participants reporting the concerns they had when enrolling or considering dropping out. One participant described the experimental nature of trials and feelings of being a ‘guinea-pig’. Some participants recalled declining involvement because the intervention or investigations were not considered to be acceptable. Personal factors impacting trial participation were discussed; age and health at the time, especially daily

fluctuations in health while on dialysis, were key factors. Taking part in trials while being on the transplant list was perceived to potentially jeopardise participants’ chances of receiving a transplant.

## DISCUSSION

The aim of this mixed-methods study was to evaluate the usage of different RCT designs in the HD population,

**Table 5** Quotes showing perceptions of the convenience of trial participation (theme 1)

Subtheme	Quotation
Trial duration	“[longer than six months would be] too time-consuming... I wouldn't be prepared to do it for a very long time” (P02)
	“kidney disease is a long term issue anyway so I don't think [longer trials] would be a problem... It's probably what you are being asked to do, is probably more the reason why people are a bit worried and leave. Don't think the design has much to do with it” (P03)
	“If I knew it would be a long trial, then I wouldn't be so keen ... and if it took up too much of my time. Then I may give it some thought [to leave the study early]” (P05)
	“Oh that doesn't matter, yeah because we've got all the time on dialysis... as long as it's on dialysis days, then we have all the time here” (P10)
	“No I think once you're on it, you know what's involved, you're committed to going through with it... I think people get concerned about longer term commitments than short term commitments” (P04)
Study visits	“I am always sick... I can't make any extra journeys than I already do... When I come here, Monday, Wednesday, Friday. I am here for 3 or 4 hours, then I am happy to take part. But to be invited on extra days, then I can't come, sorry... My body isn't prepared to come another time” (P01)
	“If [study visits] were fitted around dialysis, or done whilst we are on dialysis. Then it wouldn't take up any extra time” (P05)
	“I would leave the study [if visits were done whilst on dialysis]... because I don't feel well on dialysis and afterwards” (P06)
	“Patients don't want to be here, they want to do their best to help you but... when they finish, the first thing they want to do is leave, they want to get out and go. With research assessments and enquiries, it's the best time for you to participate with the patient while they're doing the dialysis... That is the main prime time, to do the research” (P09)
	“I wouldn't stay later but I'd come in earlier..... Maybe up to half an hour... Otherwise, I don't mind, plus when we're sat here for 4 hours, it helps us pass the time... when you have to come on another day, it affects work and everything” (P10)

**Table 6** Quotes demonstrating patients' perception to equipoise (theme 2)

Subtheme	Quotation
Perception of intervention	<p>"You're more active rather than passive... I don't think [as a control] I'm making much [difference] than just being there for a comparative basis... if you know that you're going to be a useful part of the intervention, I think that sounds more attractive to me" (P04)</p> <p>"I'd say significantly important [to get the intervention] because it could mean a change to your health, feel better and it could, if not for yourself, help other people, so that's always a good thing" (P07)</p>
Preference to intervention	"I would prefer the studies where you get the treatment at some point ... I would rather be the first person, so I get the treatment faster" (P06)
Perception of control	<p>"It is a contribution towards the study, without the risk of adverse effects" (P05)</p> <p>"with the control side of things they're not really getting any benefit whatsoever as long as they're participating so they'll drop out more" (P08)</p> <p>"...like the potassium drug, I was, so excited about it, if I wouldn't have had the drug, I would have felt let down" (P09)</p> <p>"Well, I either get it [new treatment on offer] or I don't, it doesn't matter... as long as I'm here, I'm happy to help" (P10)</p>
Preference to control	"I think I would like to be in group B [control]... because I have no idea what the treatment is doing" (P01)
Perception of parallel-group trials	"It's the normal way, to not be guaranteed the treatment" (P02)
Perception of non-standard trials	<p>"I think it is better as far as the patient is concerned... because they get the treatment at some stage" (P02)</p> <p>"If you were in a control group, you'd want to carry on and get a different type of treatment. If you were in the intervention group you might not be happy about having to become a control...although, you're contributing by being just in a control group, I think anything that gives you an opportunity to be part of an intervention process, you would go for" (P04)</p>

with a focus on reporting, recruitment and retention. The qualitative component aimed to explore the perceptions of individuals on HD towards trial designs and taking part in HD trials.

Our findings show that standard parallel-group RCT designs are the most frequently used in the HD population and is similar to a previous estimate of trials across medical specialties.<sup>21</sup> The reporting of sample size in trials assessed was poor, recruitment rates were low and retention varied by trial design. Themes extracted from the interviews were around trial duration and timing of study visits, perceptions of being allocated control or intervention arms (and how this related to perceived clinical equipoise), as well as perceptions of the adverse and beneficial effects of trial participation.

Figure 3 summarises some recommendations from the findings of the scoping review and interviews for improving recruitment and retention in future RCTs.

### Implications for trial design

An important theme extracted from this study was the duration of trials. In our review, the longest and largest trials were cluster trials, which were also less likely to achieve their target recruitment number and retain participants. Discontinuation due to the burdensome trial duration was one of the main reasons cited by our interview participants and was also noted by Kotz *et al.*<sup>22</sup> Discussing expected trial duration when approaching a patient to discuss a trial may help manage participants'

expectations and consideration of how to reduce the intensity of follow-up in longer trials may improve recruitment and retention rates.

Of the trials assessed, achievement of a significant primary end point was greatest in cluster trials (81.8%) and lowest in crossover trials (38.5%). Larger trials, such as cluster trials, were more likely to be adequately powered. For this review, achieving a significant primary end point was defined by a statistically significant result with  $p < 0.05$ . However, trials may be successful or clinically significant without needing a statistically significant value.<sup>23</sup> Shochet *et al* concluded that  $p$  values may not provide the evidence required for evidence-based medicine and therefore larger RCTs with lower attrition are needed.<sup>24</sup>

### Implications for trial conduct

Altering trial conduct to enhance the participant experience may improve recruitment and retention. Achievement of target recruitment in trials is poor across all medical specialties.<sup>25</sup> Trials involving patients on HD are no different, with between 46% and 58% of trials in this review achieving their recruitment target, in line with previous CKD literature.<sup>12</sup> The financial and scientific cost of under-recruitment to clinical trials is manifold; one institution estimated that low-enrolling trials may cost them close to \$1 million a year but derive minimal scientific benefit.<sup>26</sup>




**Table 7** Quotes demonstrating perceptions of the benefits and adverse effects of trial participation (theme 3)

Subtheme	Quotation
Individual benefits	“now the study is finished, but they kept me up on [the intervention], and it's such a good drug, it's helping me. Plus, they give you a newsletter, they let you know what's happening... Our research team is quite good. They give you that personal [touch]]. So you want to take part in research. Which makes you feel involved” (P09) “You will learn more, you can help yourself and other patients with what you learn” (P06)
Sense of giving back	“And I think I feel quite proud when I take part in a study, and it helps people” “When you do these studies, it's very important that the patient gets to know what's happening...I'd like to know what happened at the trial... sometimes we don't hear from them again” (P09)
Sense of community	“[regarding cluster trials] If you met up with a group of people that have the same problem, you will become stronger because you can talk about what affects each other” (P08) “[Doing cluster trials] might be better I think, more motivating” (P03) “[Doing cluster trials] wouldn't make a difference to me” (P04) “But [the research team] had a prize giving thing, and they all dressed up And then they had a little spread like sandwiches and cakes....they gave out certificates” (P09)
Reasons to decline	“Sometimes there can be side effects of the new drugs or treatments” (P05) “you are a guinea pig. They could go wrong” (P03) “I did turn down one research project because that meant having to have regular body scans, and I'm not very keen on going into machines” (P04) “It depends at the time how I feel. Sometimes I don't feel well enough” (P06) “I am almost 91, so [taking part] depends on my health” (P02) “If I had a transplant... It's probably what you are being asked to do, is probably more the reason why people are a bit worried and leave” (P03) “But even if I was on a transplant list, as long as it was safe and it didn't affect chances of the transplant and everything, then you'd carry on, what's wrong with it. But I think it's important to have a transplant team that can liaise with a patient” (P09)

Literature suggests embedding research into clinical care to reduce participant burden may improve recruitment and retention.<sup>27,28</sup> Most of our interview participants preferred to have study visits during dialysis. Our interviews suggest that integrating clinical visits with study visits or using routinely collected data may reduce participant burden.

Retention for all trial designs was good. Our interviews revealed that previous good experiences of taking

part in trials, such as physical benefits or ‘feel-good’ effects developed from a sense of community or fulfilment favourably influenced future participation. Focusing on fostering rapport and a sense of community may encourage continued participation in future RCTs. In our interviews, participants were disheartened to not receive feedback about outcomes from previous trial participation and felt deterred from taking part in future research.

**Figure 3** Recommendations to improve recruitment and retention of participants in randomised controlled trials in the haemodialysis population.

Ensuring participants have access to trial outcomes and are informed about which arm they received in a blinded trial demonstrates appreciation for their involvement.

Interestingly, our interviews suggest that participants perceive clinical equipoise differently to researchers. For many, getting the intervention was considered the 'best' treatment available and a reason to commit to a study; most did not understand the importance of a control arm and felt they were being denied treatment by being in this group. Participant-preconceived ideas can contribute towards 'resentful demoralisation', threatening the internal validity of a trial by leading to increased dropout rates or artificially increasing the difference in performance between the two arms of a trial.<sup>29</sup>

Post hoc review of the themes extracted found that there was little difference between the perspectives of participants with previous trial experience and those without. Those without experience seemed more wary about the effect of participation on potential transplantation. Both groups had similar preconceptions about equipoise in research; even some of those who had experienced randomisation in trials retained a belief that the intervention is better. It should be noted that this is an anecdotal observation on a small sample size and such subgroup comparisons should be viewed as hypothesis generating.

Our findings highlight the importance of educating participants about the role of the control and intervention arms and considering preconceptions about equipoise. Trials which ultimately offer the intervention to all participants during or, if possible, following trial conclusion may have better recruitment and retention. Post-trial access to interventions is recommended by the Declaration of Helsinki 2013 and should be part of the informed consent process, but the practicalities of implementation are complex.<sup>30</sup> Despite the views expressed in the interviews, the scoping review found little difference between recruitment rates of individually randomised parallel-group trials and crossover trials, where the intervention is trialled by all participants. Nevertheless, it is important to consider whether offering the intervention to all participants is appropriate and include this decision making in the design process of an RCT.

### Implications for research dissemination

The reporting of sample size in non-standard trials assessed in this scoping review was poorer than individually randomised parallel-group trials. Poor reporting does not necessarily reflect the trial conduct; however, it does make it more difficult to assess the appropriateness of methodology and the extent to which bias was mitigated, weakening confidence in the outcome and limiting the interpretation of the hypothesis. The production of the CONSORT Statement in 1996 aimed to improve the conduct and reporting of RCTs, and there have been multiple updates and extensions since.<sup>18 31 32</sup> However, only 42% of biomedical journals that endorse CONSORT make its use compulsory, with 38% providing a checklist for authors.<sup>33</sup> Standards of reporting may improve if more journals endorsing CONSORT make using a checklist compulsory.

Reviews exploring reporting of clinical trials in nephrology, endocrinology and otolaryngology have identified that between 28% and 48% of trials justified their sample size.<sup>27 34 35</sup> In this scoping review, 57.5% of all trials provided sample size justification but less than half of cluster trials, which is similar to a previous review which found suboptimal reporting in cluster trials in patients on HD.<sup>36</sup> Of the 13 crossover trials selected, only 1 paper included the requirements from the CONSORT extension for crossover trials, although some were published prior to the CONSORT extension. Sample size justification and target recruitment was reported in seven crossover trials (53.8%). While specification of target recruitment is not required by CONSORT, credibility of a study is affected as achievement of recruitment target may show if a study was feasible, acceptable to patients and able to use resources efficiently. The use of flow diagrams, recommended to help assess reliability of a trial, was lower in crossover trials, potentially due to the more complex methodology.

Aiming to increase the number of high-quality trials in nephrology, the ISN developed an 'The ISN-ACT Clinical Trials Toolkit' in 2020 which provides guidance on design, ethnics, conduct and analysis of parallel-group, crossover, cluster and factorial trial designs.<sup>37</sup> Publicising the ISN-ACT toolkit to reach a wider audience may provide researchers with more guidance and support to develop clinical trials in nephrology, especially non-standard trials such as crossover trials, in turn improving the quality of the study conducted as well as the reporting and dissemination of findings.

### STRENGTHS AND LIMITATIONS

This scoping review resulted in a comprehensive collection of HD trials from a 7-year period. Furthermore, this review assessed trials in the HD population by trial design, which has not been done previously. Databases were searched until 2019 as the pandemic postponed the interviews, delaying synthesis and integration of the data. It is unlikely that there will be significant changes in number and quality of RCTs published since 2019 as this is a much shorter timeframe than the initial search. While all cluster and stepped-wedge trials were assessed for this review, not all parallel-group and crossover trials were analysed. Nonetheless, attempts were made to reduce selection bias by using a random number generator to select the crossover and parallel-group trials.

Our interview sample size was small and from a single dialysis centre. Our data may be subject to biases related to geography, population and the types of research groups they may interacted with. However, purposive sampling was used to obtain a broad range of perspectives based on sex, age, ethnicity and previous research experience. Nevertheless, the findings from these exploratory interviews should be viewed as hypothesis generating and future research should include more participants from a wider pool of study sites.

## CONCLUSION

HD trials need to be optimised with better design, conduct and reporting. Choice of trial design should be driven by the research question and hypothesis, while taking into account participant factors that affect acceptability. Greater patient involvement when designing and planning trials, as well as timely feedback on results, will improve recruitment and retention and ensure that participants feel acknowledged for their role.

**Twitter** Sherna F Adenwalla @SAdenwalla and James O Burton @drjamesburton

**Contributors** PK and SFA—data collection, analysis, manuscript draft, figure preparation and final preparation. CJL—interview analysis and manuscript revision. DSM—data collection, statistical analysis and manuscript revision. LJG—statistical analysis and manuscript revision. JOB—study conception, data collection, manuscript revision, final approval of manuscript and responsible for the overall content as the guarantor. All authors read and approved the final manuscript.

**Funding** This project was supported by funding from Kidney Research UK (Reference: ID\_001\_20190326). CJL gratefully acknowledges salary funding from the Stoneygate Trust and support from the National Institute for Health Research Leicester Biomedical Research Centre. LJG is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication** Not required.

**Ethics approval** This study involves human participants and was approved by London-Surrey Border NHS Research Ethics Committee (REC ref: 19/L0/1816). Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request. These include full data extraction tables and interview transcriptions. Please contact the corresponding author for further details.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Prachi Kaushal <http://orcid.org/0000-0002-8012-389X>  
James O Burton <http://orcid.org/0000-0003-1176-7592>

## REFERENCES

- Yaseen M, Hassan W, Awad R, et al. Impact of recent clinical trials on nephrology practice: are we in a stagnant era? *Kidney Dis* 2019;5:69–80.
- Chatzimanouil MKT, Wilkens L, Anders H-J. Quantity and reporting quality of kidney research. *J Am Soc Nephrol* 2019;30:13–22.
- Strippoli GFM, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. *J Am Soc Nephrol* 2004;15:411–9.
- Baigent C, Herrington WG, Coresh J, et al. Challenges in conducting clinical trials in nephrology: conclusions from a kidney Disease-Improving global outcomes (KDIGO) controversies conference. *Kidney Int* 2017;92:297–305.
- Novak JE, Inrig JK, Patel UD, et al. Negative trials in nephrology: what can we learn? *Kidney Int* 2008;74:1121–7.
- Dahiru T, Aliyu A, Kene T. Statistics in medical research: misuse of sampling and sample size determination. *Ann Afr Med* 2006;5:158–61.
- Kosa SD, Monize J, Leenus A, et al. Reporting quality of pilot clinical trials in chronic kidney disease patients on hemodialysis: a methodological survey. *Pilot Feasibility Stud* 2019;5:53.
- Fishbane S, Hazzan AD, Shirazian S, et al. Quality of reporting of randomization methodology in nephrology trials. *Kidney Int* 2012;82:1144–6.
- Schulz KF, Altman DG, Moher D, et al. Consort 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010;340:c332–702.
- Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. *Lancet* 2017;390:1888–917.
- Perkovic V, Craig JC, Chailimpamontree W, et al. Action plan for optimizing the design of clinical trials in chronic kidney disease. *Kidney Int Suppl* 2017;7:138–44.
- Natale P, Gutman T, Howell M, et al. Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. *Nephrol Dial Transplant* 2020;35:755–64.
- Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol* 2014;67:1291–4.
- Munn Z, Peters MDJ, Stern C, et al. Systematic review or scoping review? guidance for authors when choosing between a systematic or scoping review approach. *BMC Med Res Methodol* 2018;18:143.
- Peters MDJ, Godfrey CM, Khalil H, et al. Guidance for conducting systematic scoping reviews. *Int J Evid Based Healthc* 2015;13:141–6.
- Kaushal P. Trial designs in haemodialysis patients: review protocol V2 Figshare, 2020. Available: [https://figshare.com/articles/preprint/Trial\\_Designs\\_in\\_Haemodialysis\\_Patients\\_Review\\_Protocol\\_docx/12053085](https://figshare.com/articles/preprint/Trial_Designs_in_Haemodialysis_Patients_Review_Protocol_docx/12053085)
- Smyth B, Haber A, Trongtrakul K, et al. Representativeness of randomized clinical trial cohorts in end-stage kidney disease: a meta-analysis. *JAMA Intern Med* 2019;179:1316–24.
- Campbell MK, Piaggio G, Elbourne DR. Statement: extension to cluster randomised trials. *BMJ : British Medical Journal* 2010;340:19–22.
- Dwan K, Li T, Altman DG, et al. Consort 2010 statement: extension to randomised crossover trials. *BMJ* 2019;366:14378.
- Braun V, Clarke V. Using thematic analysis in psychology. *Qual Res Psychol* 2006;3:77–101.
- Chan A-W, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. *Lancet* 2005;365:1159–62.
- Kotz D, Spigt M, Arts ICW, et al. Use of the stepped wedge design cannot be recommended: a critical appraisal and comparison with the classic cluster randomized controlled trial design. *J Clin Epidemiol* 2012;65:1249–52.
- van Rijn MHC, Bech A, Bouyer J, et al. Statistical significance versus clinical relevance. *Nephrology Dialysis Transplantation* 2017;315:gfww385–ii12.
- Shochet LR, Kerr PG, Polkinghorne KR. The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. *Kidney Int* 2017;92:1469–75.
- Walters SJ, Bonacho DOS Anjos Henriques-Cadby I, Bortolami O, flight L, hind D, Jacques RM, et al. recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom health technology assessment programme. *BMJ Open* 2017;7:e015276.
- Kitterman DR, Cheng SK, Dilts DM, et al. The prevalence and economic impact of low-enrolling clinical studies at an academic medical center. *Acad Med* 2011;86:1360–6.
- Selewski DT, Herreshoff EG, Gipson DS. Optimizing enrollment of patients into nephrology research studies. *Clin J Am Soc Nephrol* 2016;11:512–7.
- Nicholls SG, Carroll K, Weijer C, et al. Ethical issues in the design and conduct of pragmatic cluster randomized trials in hemodialysis care: an interview study with key stakeholders. *Can J Kidney Health Dis* 2020;7:205435812096411.
- Bradley C. Designing medical and educational intervention studies. A review of some alternatives to conventional randomized controlled trials. *Diabetes Care* 1993;16:509–18.

- 30 World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. *Jama* 2013;310:2191–4.
- 31 Ioannidis JPA, Evans SJW, Gotzsche PC, *et al.* Better reporting of harms in randomized trials: an extension of the CONSORT statement. *Ann Intern Med* 2004;141:781–8.
- 32 Begg C, Cho M, Eastwood S, *et al.* Improving the quality of reporting of randomized controlled trials. The CONSORT statement. *JAMA* 1996;276:637–9.
- 33 Shamseer L, Hopewell S, Altman DG, *et al.* Update on the endorsement of CONSORT by high impact factor journals: a survey of journal "Instructions to Authors" in 2014. *Trials* 2016;17:301.
- 34 Rios LP, Oduyungbo A, Moitri MO, *et al.* Quality of reporting of randomized controlled trials in general endocrinology literature. *J Clin Endocrinol Metab* 2008;93:3810–6.
- 35 Huang YQ, Traore K, Ibrahim B, *et al.* Reporting quality of randomized controlled trials in otolaryngology: review of adherence to the CONSORT statement. *J Otolaryngol Head Neck Surg* 2018;47:34.
- 36 Al-Jaishi AA, Carroll K, Goldstein CE, *et al.* Reporting of key methodological and ethical aspects of cluster trials in hemodialysis require improvement: a systematic review. *Trials* 2020;21:752.
- 37 Smyth B, Wheeler DC, Hiemstra TF. ISN-ACT clinical trials toolkit International Society of Nephrology, 2020. Available: <https://www.theisn.org/isn-act-toolkit>



## Supplementary

### Appendix 1 – Search terms

**Table 1: Search strategy and search terms used for MEDLINE**

	Search term	Field
1	“Renal Dialysis”	TI, AB
2	Haemodialysis	TI, AB
3	Hemodialysis	TI, AB
4	Dialysis	TI, AB
5	Trial	TI, AB
6	“Randomized controlled trial”	TI, AB
7	“Randomised controlled trial”	TI, AB
8	(Parallel adj5 trial)	TI, AB
9	(Parallel-group adj5 trial)	TI, AB
10	(Crossover adj5 trial)	TI, AB
11	(Cross-over adj5 trial)	TI, AB
12	(Cluster adj5 trial)	TI, AB
13	(Stepped wedge adj5 trial)	TI, AB
14	(Stepped-wedge adj5 trial)	TI, AB
15	1OR2OR3OR4	
16	5OR6OR7OR8OR9OR10OR11OR12OR 13 OR 14	
17	15 AND 16	
18	Limit 17 to yr=“2013-2019”	

TI, title; AB,abstract

## Appendix 2 – Data Extraction Forms

**Table 1: Table representing data items extracted for parallel-group studies, with notes to reviewer for data extraction**

<b>Data to be extracted</b>	<b>Notes to reviewer</b>
<b>Study ID</b>	
<b>Title</b>	
<b>Author</b>	
<b>Year Published</b>	
<b>Country</b>	
<b>Intervention type</b>	Pharmacological, device, procedure, lifestyle or other
<b>Type of trial</b>	Pilot/Feasibility/Full trial
<b>States how sample size was determined?</b>	Yes/No
<b>Number of participants recruited</b>	Defined as number who consented
<b>Number of participants that finished trial</b>	
<b>Achieved target recruitment?</b>	Yes/No (note what target recruitment was)
<b>Patient retention</b>	Percentage: number of participants who finished trial/number of participants recruited
<b>Patient attrition</b>	Percentage: number of participants who were lost to follow up/number of participants recruited
<b>Lost to follow up due to withdrawal of consent</b>	Number of participants that chose to withdraw their consent
<b>Percentage lost to follow up due to withdrawal of consent</b>	Number of participants that chose to withdraw consent/total number of participants that left the trial
<b>Use of CONSORT or flow diagram</b>	Yes/No
<b>Achieved statistically significant primary outcome</b>	Yes/No
<b>Length of trial</b>	In months. State whether data is for length of trial or length of intervention

**Table 2: Table representing data items extracted for crossover studies, with notes to reviewer for data extraction**

<b>Data to be extracted</b>	<b>Notes to reviewer</b>
<b>Study ID</b>	
<b>Title</b>	
<b>Author</b>	
<b>Year Published</b>	
<b>Country</b>	
<b>Intervention type</b>	Pharmacological, device, procedure, lifestyle or other
<b>Type of trial</b>	Pilot/Feasibility/Full trial
<b>States how sample size was determined?</b>	Yes/No
<b>Was within participant variability accounted for?</b>	Yes/No
<b>Number of participants recruited</b>	Defined as number who consented
<b>Number of participants that finished trial</b>	
<b>Achieved target recruitment?</b>	Yes/No (note what target recruitment was)
<b>Patient retention</b>	Percentage: number of participants who finished trial/number of participants recruited
<b>Patient attrition</b>	Percentage: number of participants who were lost to follow up/number of participants recruited
<b>Lost to follow up due to withdrawal of consent</b>	Number of participants that chose to withdraw their consent
<b>Percentage lost to follow up due to withdrawal of consent</b>	Number of participants that chose to withdraw consent/total number of participants that left the trial
<b>Use of CONSORT or flow diagram</b>	Yes/No
<b>Achieved statistically significant primary outcome</b>	Yes/No
<b>Length of trial</b>	In months. State whether data is for length of trial or length of intervention

**Table 3: Table representing data items extracted for cluster studies, with notes to reviewer for data extraction**

<b>Data to be extracted</b>	<b>Notes to reviewer</b>
<b>Study ID</b>	
<b>Title</b>	
<b>Author</b>	
<b>Year Published</b>	
<b>Country</b>	
<b>Intervention type</b>	Pharmacological, device, procedure, lifestyle or other
<b>Type of trial</b>	Pilot/Feasibility/Full trial
<b>Is there sample size justification?</b>	Yes/No
<b>Does it provide number of clusters in sample size calculation?</b>	Yes/No
<b>Does it provide cluster size?</b>	Yes/No
<b>Does it state if equal or unequal cluster sizes are assumed?</b>	Yes/No
<b>Does it state the ICC?</b>	Yes/No
<b>Does it state uncertainty in ICC?</b>	Yes/No
<b>How was the cluster formed?</b>	Dialysis shift/HD centre
<b>Number of participants recruited</b>	Defined as number who consented
<b>Number of participants that finished trial</b>	
<b>Achieved target recruitment?</b>	Yes/No (note what target recruitment was)
<b>Patient retention</b>	Percentage: number of participants who finished trial/number of participants recruited
<b>Patient attrition</b>	Percentage: number of participants who were lost to follow up/number of participants recruited



<b>Lost to follow up due to withdrawal of consent</b>	Number of participants that chose to withdraw their consent
<b>Percentage lost to follow up due to withdrawal of consent</b>	Number of participants that chose to withdraw consent/total number of participants that left the trial
<b>Use of CONSORT or flow diagram</b>	Yes/No
<b>Achieved statistically significant primary outcome</b>	Yes/No
<b>Length of trial</b>	In months. State whether data is for length of trial or length of intervention

## Appendix 3 - Interview Topic Guide



### Patient Interview Topic Guide

#### Introduction

"Firstly, we would like to welcome you to the interview and thank you for agreeing to speak to us. The reason we have asked you to take part in this discussion is that we would like to understand more about different types of research in haemodialysis patients, and how they feel towards different types of research design. This is important because very little is currently known about patients' views on this subject. We will not be asking you for your personal experiences here, unless you want to offer them, but just your opinions as a patient. If you would like further information, please ask at the end.

Before we begin we would like to remind you that whatever you say here will be anonymous. Your name and personal details will not be mentioned in any report.

We are using a digital recorder to record our conversation because it is difficult for us to write down everything you say. However, no personal identifiable data will be recorded and a participant number will be allocated to you. This will also enable us to give you our full attention and listen to what you have to say."

#### Any questions before we start?

1. Introductions (us and participants, name, and for patients, how long have you been a kidney patient, have you ever taken part in a clinical trial as a haemodialysis (or other) patient)

#### General Views on Research

2. Firstly, we would like to talk to you very generally about Research. To start us off, what comes to mind when you think of the word 'Research'?
3. What do you think are the benefits of research?
  - a. For the participant
  - b. For the wider public
4. What do you think are the disadvantages of research?

#### Introduce trial designs

Historically, studies involving participants with kidney disease have often failed to recruit enough patients and there is a high rate of participants leaving the study before it is over. There may be many reasons for this. However, it affects the strength of the study and how much information we can learn from it. Trials in this population are usually parallel group RCTs (will explain later). One proposal is that by changing the design of the trial, it may be

possible to improve recruitment and retention, so we wanted to discuss some alternative, novel trial designs and to get your views on them.

**Run through the different trial designs on PowerPoint/paper copies.** Explain parallel group is the traditional one and the ones that follow are newer designs and fewer studies in kidney patients have used them yet.

For **each** trial design

5. What do you think of this design?
6. What would make you want to join a study with this design?
7. What would put you off joining a study with design?
8. If you agreed to take part in a study of this design, what might make you leave the study early? What might encourage you to complete the study?
9. What do you think of the way participants are allocated to arms in this study design?
  - a. How would this affect your decision to join a study, or to stay in the study?

**After going through all trial designs:**

10. As you can see in some study designs, as a participant you would receive the new treatment at some point, whereas in other studies, if you were allocated to the control, you wouldn't receive the new intervention during the study.
  - a. How would this make you feel?
  - b. How important is it to you that you get the treatment on offer?
  - c. How would this impact your participation in the study?
  - d. If you were allocated to an arm where you did not get the treatment/intervention on offer at all, how would you feel about this?
  - e. How would it affect your motivation to stay in the study?
  - f. How would you feel about being in a trial where you spent time having the treatment but also the control?
11. Would you prefer to be in a trial that ensured you had the treatment on offer even if it were a longer trial?
12. We know that some studies in HD patients managed to recruit the correct amount of people they needed for the study and other study designs were less able to do this. Does this surprise you? Why do you think this might be?
13. We also found that some studies had more people dropping out of studies compared to others, does this surprise you? Why do you think this might be?
14. How would the length of a trial affect your decision to join a study? What do you consider is 'too long' for a study follow up? What do you think is the ideal length of time to be in a study?
  - a. How could the burden of follow up be reduced?

- b. Would the amount of follow up factor into your decision on whether to join or continue with the study?
15. Are there any potential other factors to do with your health or management that might impact on you volunteering to take part in a trial?  
(if necessary to prompt)- some people have mentioned about being on the transplant list or perhaps concerned about switching dialysis times, how would you feel about that?
16. Anything else you would like to say/or any questions?
17. Is there anything you feel we have missed out or thought we would cover that you would like to discuss?

**End**


**Closing and thanks** - check that the participant is still happy for you to use all the information provided and offer the possibility to erase sections of the recording. **Reiterate anonymity etc.**


Thank them for their time and contribution.


**Contact details and what next.**




Appendix 4 – Visual Aids for Interviews











Appendix 5 – Included studies

Table 1: Individually randomised parallel-group trials selected for review

Author	Year	Country	Intervention Type	Study groups	LoS in mths	Justification of SS	No. of ppts at start	No. of ppts at end	Achieved target recruitment	Retention rate(%)	% of ppts lost due to WOC	Use of flow diagram	Achieved stat. sig. endpoint
Akrami et al (6)	2016	Iran	Lifestyle	1: FP 2: Placebo	4	No	79	63	NR	79.8	87.5	Yes	Yes
Bacci et al (7)	2018	Brazil	Procedure	1: RICP 2: Ctrl	NR	No	47	NR	Yes	NR	NR	No	No
Bansal et al (8)	2014	India	Pharm	1: Cholecalciferol 2: Ctrl	5	Yes	45	27	Yes	60	0	Yes	No
Gaweda et al (9)	2014	USA	Pharm	1: Ctrl 2: SAM	17	Yes	62	52	Yes	83.9	10	Yes	Yes
Gobo-Oliveira et al (10)	2018	Brazil	Pharm	1: Gabapentin 2: DEX	17	Yes	60	58	Yes	96.7	0	Yes	No
Hassanzadeh et al (11)	2018	Iran	Other (Alt.)	1: Relaxation 2: Aromatherapy 3: Ctrl	10	Yes	105	NR	Yes	NR	NR	No	Yes
Huan-Sheng et al (12)	2016	Taiwan	Device	1: BCM-BIS 2: SC	12	Yes	298	251	No	84.2	27.7	Yes	No
Khosroshahi et al (5)	2013	Iran	Lifestyle	1: Omega-3 2: Placebo	NR	Yes	100	88	Yes	88	0	No	Yes
Lenglet et al (13)	2017	France	Pharm	1: Nicotinamide 2: Sevelamer	60	Yes	100	73	No	73	NR	Yes	No
Loutradis et al (14)	2019	Slovenia and Greece	Procedure	1: Lung US 2: Ctrl	NR	Yes	71	67	Yes	94.4	0	Yes	Yes

<b>Makhlough et al (15)</b>	2016	Iran	Pharm	1: Hybrid therapy 2: Standard triple therapy	NR	No	40	40	NR	100	0	Yes	Yes
<b>Martins do Valle et al (16)</b>	2019	Brazil	Lifestyle	1: ID Ex 2: Ctrl	NR	No	24	19	NR	79.2	0	Yes	No
<b>Momennasab et al (17)</b>	2018	Iran	Other (Alt.)	1: ID Music 2: Music at night 3: Ctrl	8	Yes	105	102	Yes	97.1	33.3	Yes	Yes
<b>Morena et al (18)</b>	2017	France	Device	1: HFHD 2: OLHDF	84	Yes	381	261	Yes	68.5	NR	Yes	Yes
<b>Nahidi et al (19)</b>	2018	Iran	Other (Alt.)	1: Acupuncture 2: Sham	24	Yes	30	26	Yes	86.7	100	Yes	Yes
<b>Obi et al (20)</b>	2016	Japan	Lifestyle	1: Vitamin B6 2: Ctrl	NR	Yes	60	44	NR	73.3	0	Yes	Yes
<b>Rad et al (21)</b>	2017	Iran	Procedure	1: Cool dialysate 2: Ctrl	4	Yes	60	60	Yes	100	0	Yes	Yes
<b>Rhee et al (22)</b>	2017	USA	Lifestyle	1: High protein 2: Low protein	NR	Yes	110	106	Yes	96.4	NR	Yes	Yes
<b>Ronco et al (23)</b>	2017	Italy	Device	1: NV dialyzer 2: Standard	NR	Yes	19	17	No	89.5	0	No	No
<b>Schardong et al (24)</b>	2017	Brazil	Procedure	1: NMES 2: Ctrl	9	Yes	24	21	Yes	87.5	100	Yes	Yes
<b>Schlosser et al (25)</b>	2016	Germany	Procedure	1: TPTX + AT 2: TPTX	72	Yes	100	74	Yes	74	34.6	Yes	Yes
<b>Siriopol et al (26)</b>	2017	Romania	Device	1: Lung US 2: SC	25	Yes	250	241	No	96.4	0	Yes	No
<b>Tayebi et al (27)</b>	2019	Iran	Lifestyle	1: Ctrl 2: BCAA + Ex 3: Ex	NR	No	51	48	NR	94.1	NR	Yes	Yes
<b>Thadhani et al (28)</b>	2017	USA	Lifestyle	1: Oral Vitamin D 2: Placebo	5	Yes	62	53	Yes	85.5	22.2	Yes	Yes

Xavier et al (29)	2015	Brazil	Device	1: CPAP 2: Ctrl	NR	No	40	37	NR	92.5	66.7	Yes	Yes
Ziaee et al (30)	2019	Iran	Pharm	1: Spironolactone 2: Ctrl	NR	No	48	43	NR	89.6	0	No	Yes

Alt., alternative therapies; BCAA, branched chain amino acids; BCM-BIS, bioimpedance spectroscopy; CPAP, continuous positive airway pressure; Ctrl, control; DEX, dexchlorpheniramine; Ex, exercise; FP, fumaria parviflora L; HFHD, high-flux haemodialysis; ID, intradialytic; Lol, length of intervention; LoS, length of study; Mnths, months; NMES, neuromuscular electrical stimulation; No., number; NR, not reported; OLHDF, online hemodiafiltration; Pharm, pharmacological; Ppt(s), participant(s); RICP, remote ischaemic preconditioning; SAM, smart anaemia manager; SC, standard care; SS, sample size; SSC, sample size calculation; Stat. sig., statistically significant; TPTX + AT, total parathyroidectomy with autotransplantation; TPTX, total parathyroidectomy; UC, unclear; US, ultrasound; WoC, withdrawal of consent

Table 2: Crossover trials selected for review

Author	Year	Country	Intervention Type	Study groups	LoS in mths	Justification of SS	Within pharmaceutical counterfor	No. of ppts at start	No. of ppts at end	Achieved target recruitment	Retention rate(%)	% of ppts lost due to WOC	Use of flow diagram	Achieved stat.sig endpoint
De Sequera et al (31)	2019	Spain	Pharm	1: CDF 2: ADF	8	No	No	56	46	NR	82.1	UC	Yes	No
Eljaoudi et al (32)	2015	Morocco	Other (Alt.)	1: Argan oil 2: Ctrl	NR	Yes	No	37	NR	Yes	NR	NR	No	Yes
Ettema et al (33)	2018	The Netherlands	Procedure	1: Standard HD 2: HD with BF	6	Yes	No	30	29	Yes	96.7	0	Yes	Yes
Jeong et al (34)	2018	USA	Lifestyle	1: Ctrl 2: ID Ex in 1 <sup>st</sup> hr 3: ID Ex in 3 <sup>rd</sup> hr	UC	No	No	12	8	NR	66.7	75	No	NR
Leung et al (35)	2017	Canada	Device	1: Ctrl 2: HD with BF	12	Yes	No	35	26	Yes	74.3	0	Yes	No
Orcy et al (36)	2014	Brazil	Lifestyle	1: Ctrl 2: ID Ex	9	No	No	24	22	NR	91.7	0	Yes	No
Razeghi et al (37)	2015	Iran	Pharm	1: Sertraline 2: Placebo	20	No	No	NR	12	NR	NR	UC	No	Yes
Rivara et al (38)	2015	USA	Lifestyle	1: Pom juice 2: Pom extract	8	No	No	35	20	NR	57.1	46.7	Yes	Yes
Shahgholian et al (39)	2014	Iran	Device	1: Standard HD 2: SSUF 3: SDFR	NR	No	No	NR	32	NR	NR	NR	No	No
Smith et al (40)	2017	USA	Pharm	1: 4 mEq/L Ac 2: 8 mEq/L Ac	UC	Yes	No	11	10	Yes	90.9	100	Yes	Yes

<b>Thompson et al (41)</b>	2016	Canada	Device	1: Two high flux 2: Standard HD	UC	Yes	No	33	31	Yes	93.1	0	Yes	No
<b>Tsai et al (42)</b>	2019	Taiwan	Lifestyle	1: VLP diet 2: LP diet	6	Yes	No	35	29	Yes	82.9	83.3	Yes	No
<b>Wu et al (43)</b>	2013	Taiwan	Procedure	1: SLED 2: CVVH	NR	Yes	Yes	12	10	Yes	83.3	0	Yes	No

Ac, acetate; ADF, dialysis fluid containing acetate; Alt., alternative therapies; BF, biofeedback; CDF, dialysis fluid containing citrate; Ctrl, control; CVVH, continuous veno-venous haemofiltration; Ex, exercise; HD, haemodialysis; ID, intradialytic; LoI, length of intervention; LoS, length of study; LP, low phosphate; Mnths, months; No., number; NR, not reported; Pharm, pharmacological; Pom, pomegranate; Ppt(s), participant(s); SC, standard care; SDFR, stepwise dialysis solution flow rate profiles; SLED, sustained low-efficiency dialysis; SS, sample size; SSC, sample size calculation; SSUF, stepwise sodium and ultrafiltration profiles; Stat. sig., statistically significant; UC, unclear; VLP, very low phosphate; WoC, withdrawal of consent



Table 3: Cluster trials for review

Author	Year	Country	Intervention Type	Study groups	LoS (LoI) in mths	SS requirements from CONSORT statement						Cluster formation	No. of ppts at start	No. of ppts at end	Achieved target recruitment	Retention rate (%)	% of ppts lost due to WoC	Use of flow diagram	Achieved stat. sig. endpoint
						Justification of SS	Stated no. of clusters in SSC	Stated CS	Stated if equal or unequal ICC assumed	Stated ICC	Stated uncertainty in ICC								
Bennett et al (45)	2013	Australia	LS	1: NS 2: SC	UC	No	No	No	No	No	No	HDC	96	81	Yes	84.4	0	No	Yes
Bennett et al (44)	2015	Australia	LS S/W	3 groups ID Ex	UC (36)	Yes	Yes	Yes	No	Yes	No	HDC	228	113	Yes	49.6	27.8	Yes	Yes
Birdee et al (46)	2015	USA	LS	1: ID Yoga 2: E/P	UC	No	No	No	No	No	No	D/S	31	26	Yes	83.9	40	Yes	Yes
Griva et al (47)	2018	Singapore	Other (PBE)	1: S/M 2: SC	39	No	No	No	No	No	No	D/S	259	195	NR	82.1	57.8	Yes	Yes
Griva et al (48)	2019	Singapore	Other (PBE)	1: SC 2: S/M	NR	No	No	No	No	No	No	D/S	44	42	No	95.5	0	Yes	Yes
Huang et al (49)	2018	China	Other (PBE)	1: S/M 2: SC	UC	No	No	No	No	No	No	D/S	90	83	Yes	92.2	28.6	Yes	Yes
Karavetian et al (50)	2013	Lebanon	Other (PBE)	1: SMDC 2: EG 3: Ctrl	NR (2)	No	No	No	No	No	No	D/S	122	87	NR	72	11.4	No	Yes
Karavetian et al (51)	2015	Lebanon	Other (PBE)	1: Full 2: SC 3: Partial	12	Yes	No	Yes	No	No	No	D/S	570	394	No	69.1	18.2	Yes	Yes
Weisbord et al (52)	2013	USA	Other	1: F/B 2: NM	28 (12)	Yes	No	No	No	No	No	D/S	315	186	NR	59	27.1	Yes	No

Wileman et al (53)	2016	UK	Other (PBE)	1: S/A 2: Ctrl	UC	Yes	No	No	No	No	No	D/S	91	60	Yes	65.9	UC	Yes	Yes
Wileman et al (54)	2014	UK	Other (PBE)	1: S/A 2: Ctrl	UC	Yes	No	No	No	No	No	D/S	119	90	Yes	75.6	17.2	Yes	No

Alt., alternative therapies; CS, cluster size; Ctrl, control; D/S, dialysis shift; E/G, educational games; E/P, educational program; Ex, exercise; F/B, feedback arm; HDC, haemodialysis centre; ICC, intracluster correlation coefficient; ID, intradialytic; Lol, length of intervention; LoS, length of study; LS, lifestyle; Mngt, management; Mths, months; NM, nurse management; No., number; NR, Not reported; NS, nutrition screening; PBE, Psychological, behavioural and educational; Pharm, pharmacological; Ppt(s), participant(s); S/A, self-affirmation; S/M, self-management; S/W, stepped-wedge; SC, standard care; SMDC, self-management dietary counselling; SS, sample size; SSC, sample size calculation; Stat.sig., statistically significant; UC, unclear; WoC, withdrawal of consent

## References

1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ (Clinical research ed)*. 2019;366:l4898.
2. Sterne JAC, Savović J, Page MJ, et al. RoB 2 tool.
3. Bhargava R, Kalra PA, Hann M, Brenchley P, Hurst H, Hutchison AJ. A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. *BMC nephrology*. 2019;20(1):37.
4. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, et al. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. *The New England Journal of Medicine*. 2019;380(5):447-58.
5. Tayebi-Khosroshahi H, Dehgan R, Habibi Asl B, Safaian A, Panahi F, Estakhri R, et al. Effect of omega-3 supplementation on serum level of homocysteine in hemodialysis patients. *Iran J Kidney Dis*. 2013;7(6):479-84.
6. Akrami R, Hashempur M, Tavakoli A, Nimrouzi M, Sayadi M, Roodaki M, et al. Effects of *Fumaria parviflora* L on Uremic Pruritus in Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. *Jundishapur Journal of Natural Pharmaceutical Products*. 2016;inpress.
7. Bacci MR, Vasconcelos LY, Murad N, Chagas ACP, Capuano AC, Alves BC, et al. Remote ischemic preconditioning in myocardial protection in hemodialysis patients. *Int J Gen Med*. 2018;11:175-8.
8. Bansal B, Bansal SB, Mithal A, Kher V, Marwaha R, Singh P, et al. A randomized controlled trial of cholecalciferol supplementation in patients on maintenance hemodialysis. *Indian J Endocrinol Metab*. 2014;18(5):655-61.
9. Gaweda AE, Aronoff GR, Jacobs AA, Rai SN, Brier ME. Individualized anemia management reduces hemoglobin variability in hemodialysis patients. *J Am Soc Nephrol*. 2014;25(1):159-66.
10. Gobo-Oliveira M, Pigari VG, Ogata MS, Miot HA, Ponce D, Abbade LP. Gabapentin versus dexchlorpheniramine as treatment for uremic pruritus: a randomised controlled trial. *European Journal of Dermatology*. 2018;28(4):488-95.
11. Hassanzadeh M, Kiani F, Bouya S, Zarei M. Comparing the effects of relaxation technique and inhalation aromatherapy on fatigue in patients undergoing hemodialysis. *Complement Ther Clin Pract*. 2018;31:210-4.
12. Huan-Sheng C, Yeong-Chang C, Ming-Hsing H, Fan-Lieh T, Chu-Cheng L, Tsai-Kun W, et al. Application of bioimpedance spectroscopy in Asian dialysis patients (ABISAD-III): a randomized controlled trial for clinical outcomes. *Int Urol Nephrol*. 2016;48(11):1897-909.
13. Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire-Hurtel AS, et al. Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study. *Nephrol Dial Transplant*. 2017;32(5):870-9.
14. Loutradis C, Sarafidis PA, Ekart R, Papadopoulos C, Sachpekidis V, Alexandrou ME, et al. The effect of dry-weight reduction guided by lung ultrasound on ambulatory blood pressure in hemodialysis patients: a randomized controlled trial. *Kidney International*. 2019;95(6):1505-13.

15. Makhloogh A, Fakheri H, Hojati S, Hosseini V, Bari Z. A Comparison between Hybrid Therapy and Standard Triple Therapy for *Helicobacter pylori* Eradication in Patients with Uremia: A Randomized Clinical Trial. *Middle East J Dig Dis*. 2016;8(1):39-43.
16. Martins do Valle F, Valle Pinheiro B, Almeida Barros AA, Ferreira Mendonça W, de Oliveira AC, de Oliveira Werneck G, et al. Effects of intradialytic resistance training on physical activity in daily life, muscle strength, physical capacity and quality of life in hemodialysis patients: a randomized clinical trial. *Disabil Rehabil*. 2019:1-7.
17. Momennasab M, Ranjbar M, Najafi SS. Comparing the effect of listening to music during hemodialysis and at bedtime on sleep quality of hemodialysis patients: A randomized clinical trial. *European Journal of Integrative Medicine*. 2018;17:86-91.
18. Morena M, Jaussent A, Chalabi L, Leray-Moragues H, Chenine L, Debure A, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to low-flux hemodialysis in the elderly. *Kidney International*. 2017;91(6):1495-509.
19. Nahidi Y, Badiie S, Torabi S, Abbasi Shaye Z, Nazemian F, Saki A. Acupuncture Effect on Pruritus in Hemodialysis Patients: A Randomized Clinical Trial. *Iran Red Crescent Med J*. 2018;20(10):e65521.
20. Obi Y, Mikami S, Hamano T, Obi Y, Tanaka H, Shimomura A, et al. Intravenous Vitamin B6 Increases Resistance to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: A Randomized Controlled Trial. *J Ren Nutr*. 2016;26(6):380-90.
21. Rad M, Jaghoury E, Sharifipour F, Rakhshani MH. THE EFFECTS OF COOL DIALYSATE ON PRURITUS STATUS DURING HEMODIALYSIS OF PATIENTS WITH CHRONIC RENAL FAILURE: A CONTROLLED RANDOMIZED CLINICAL TRIAL. *IRANIAN RED CRESCENT MEDICAL JOURNAL (IRCMJ)*. 2017;19(1):0-.
22. Rhee CM, You AS, Koontz Parsons T, Tortorici AR, Bross R, St-Jules DE, et al. Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial. *Nephrol Dial Transplant*. 2017;32(7):1233-43.
23. Ronco C, Brendolan A, Nalesso F, Zanella M, De Cal M, Corradi V, et al. Prospective, Randomized, Multicenter, Controlled Trial (TRIATHRON 1) on a New Antithrombogenic Hydrophilic Dialysis Membrane. *Int J Artif Organs*. 2017;40(5):234-9.
24. Schardong J, Dipp T, Bozzeto CB, da Silva MG, Baldissera GL, Ribeiro RC, et al. Effects of Intradialytic Neuromuscular Electrical Stimulation on Strength and Muscle Architecture in Patients With Chronic Kidney Failure: Randomized Clinical Trial. *Artif Organs*. 2017;41(11):1049-58.
25. Schlosser K, Bartsch DK, Diener MK, Seiler CM, Bruckner T, Nies C, et al. Total Parathyroidectomy With Routine Thymectomy and Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism: Results of a Nonconfirmatory Multicenter Prospective Randomized Controlled Pilot Trial. *Ann Surg*. 2016;264(5):745-53.
26. Siriopol D, Onofriescu M, Voroneanu L, Apetrii M, Nistor I, Hogas S, et al. Dry weight assessment by combined ultrasound and bioimpedance monitoring in low cardiovascular risk hemodialysis patients: a randomized controlled trial. *Int Urol Nephrol*. 2017;49(1):143-53.
27. Tayebi M, Tayebi A, Einollahi B, Ebadi A, Jafari A. Isometric Resistance Training and Branched-Chain Amino Acids Supplementation Can Improve Dialysis Adequacy: A Clinical Trial. *Nephro-Urol Mon*. 2019;11(2):e91175.

28. Thadhani R, Zella JB, Knutson DC, Blaser WJ, Plum LA, Clagett-Dame M, et al. 2MD (DP001), a Single Agent in the Management of Hemodialysis Patients: A Randomized Trial. *Am J Nephrol.* 2017;45(1):40-8.
29. Xavier VB, Roxo RS, Miorin LA, Dos Santos Alves VL, Dos Santos Sens YA. Impact of continuous positive airway pressure (CPAP) on the respiratory capacity of chronic kidney disease patients under hemodialysis treatment. *Int Urol Nephrol.* 2015;47(6):1011-6.
30. Ziaee SAR, Karvandi M, Ziaee NS, Ghozloujeh ZG, Shahrabaf M, Roshan A. Effects of spironolactone on cardiovascular complications in hemodialysis patients of taleghani hospital during the period of 2016-2017: A randomized double-blind controlled clinical trial. *Iranian Heart Journal.* 2019;20:45-52.
31. de Sequera Ortiz P, Pérez García R, Molina Nuñez M, Muñoz González RI, Álvarez Fernández G, Mérida Herrero E, et al. Prospective randomised multicentre study to demonstrate the benefits of haemodialysis without acetate (with citrate): ABC-treat Study. Acute effect of citrate. *Nefrologia.* 2019;39(4):424-33.
32. Eljaoudi R, Elkabbaj D, Bahadi A, Ibrahimi A, Benyahia M, Errasfa M. Consumption of Argan Oil Improves Anti-Oxidant and Lipid Status in Hemodialysis Patients. *Phytother Res.* 2015;29(10):1595-9.
33. Ettema EM, Kuipers J, van Faassen M, Groen H, van Roon AM, Lefrandt JD, et al. Effect of plasma sodium concentration on blood pressure regulators during hemodialysis: a randomized crossover study. *BMC Nephrol.* 2018;19(1):214.
34. Jeong JH, Biruete A, Fernhall B, Wilund KR. Effects of acute intradialytic exercise on cardiovascular responses in hemodialysis patients. *Hemodial Int.* 2018;22(4):524-33.
35. Leung KCW, Quinn RR, Ravani P, Duff H, MacRae JM. Randomized Crossover Trial of Blood Volume Monitoring-Guided Ultrafiltration Biofeedback to Reduce Intradialytic Hypotensive Episodes with Hemodialysis. *Clin J Am Soc Nephrol.* 2017;12(11):1831-40.
36. Orcy R, Antunes MF, Schiller T, Seus T, Böhlke M. Aerobic exercise increases phosphate removal during hemodialysis: a controlled trial. *Hemodial Int.* 2014;18(2):450-8.
37. Razeghi E, Dashti-Khavidaki S, Nassiri S, Abolghassemi R, Khalili H, Hashemi Nazari SS, et al. A randomized crossover clinical trial of sertraline for intradialytic hypotension. *Iran J Kidney Dis.* 2015;9(4):323-30.
38. Rivara MB, Mehrotra R, Linke L, Ruzinski J, Ikizler TA, Himmelfarb J. A pilot randomized crossover trial assessing the safety and short-term effects of pomegranate supplementation in hemodialysis patients. *J Ren Nutr.* 2015;25(1):40-9.
39. Shahgholian N, Salehi A, Mortazavi M. Impact of stepwise sodium and ultra filtration profiles and dialysis solution flow rate profile on dialysis adequacy. *Iran J Nurs Midwifery Res.* 2014;19(5):537-41.
40. Smith WB, Gibson S, Newman GE, Hendon KS, Askelson M, Zhao J, et al. The dynamics of the metabolism of acetate and bicarbonate associated with use of hemodialysates in the ABChD trial: a phase IV, prospective, single center, single blind, randomized, cross-over, two week investigation. *BMC Nephrol.* 2017;18(1):273.
41. Thompson S, Manns B, Lloyd A, Hemmelgarn B, MacRae J, Klarenbach S, et al. Impact of using two dialyzers in parallel on phosphate clearance in hemodialysis patients: a randomized trial. *Nephrology Dialysis Transplantation.* 2016;32(5):855-61.
42. Tsai WC, Wu HY, Peng YS, Hsu SP, Chiu YL, Yang JY, et al. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial. *Clin J Am Soc Nephrol.* 2019;14(10):1475-83.

43. Wu VC, Huang TM, Shiao CC, Lai CF, Tsai PR, Wang WJ, et al. The hemodynamic effects during sustained low-efficiency dialysis versus continuous veno-venous hemofiltration for uremic patients with brain hemorrhage: a crossover study. *J Neurosurg*. 2013;119(5):1288-95.
44. Bennett PN, Fraser S, Barnard R, Haines T, Ockerby C, Street M, et al. Effects of an intradialytic resistance training programme on physical function: a prospective stepped-wedge randomized controlled trial. *Nephrology Dialysis Transplantation*. 2015;31(8):1302-9.
45. Bennett PN, Miller MD, Woodman RJ, Hill K, Murray S, Gleadle JM. Nutrition screening by nurses in dialysis. *J Clin Nurs*. 2013;22(5-6):723-32.
46. Birdee GS, Rothman RL, Sohl SJ, Wertenbaker D, Wheeler A, Bossart C, et al. Feasibility and Safety of Intradialysis Yoga and Education in Maintenance Hemodialysis Patients. *J Ren Nutr*. 2015;25(5):445-53.
47. Griva K, Nandakumar M, Ng J-aH, Lam KFY, McBain H, Newman SP. Hemodialysis Self-management Intervention Randomized Trial (HED-SMART): A Practical Low-Intensity Intervention to Improve Adherence and Clinical Markers in Patients Receiving Hemodialysis. *American Journal of Kidney Diseases*. 2018;71(3):371-81.
48. Griva K, Rajeswari M, Nandakumar M, Khoo EYH, Lee VYW, Chua CG, et al. The combined diabetes and renal control trial (C-DIRECT) - a feasibility randomised controlled trial to evaluate outcomes in multi-morbid patients with diabetes and on dialysis using a mixed methods approach. *BMC nephrology*. 2019;20(1):2-.
49. Huang B, Li Z, Wang Y, Xia J, Shi T, Jiang J, et al. Effectiveness of self-management support in maintenance haemodialysis patients with hypertension: A pilot cluster randomized controlled trial. *Nephrology (Carlton)*. 2018;23(8):755-63.
50. Karavetian M, Ghaddar S. Nutritional education for the management of osteodystrophy (nemo) in patients on haemodialysis: a randomised controlled trial. *J Ren Care*. 2013;39(1):19-30.
51. Karavetian M, de Vries N, Elzein H, Rizk R, Bechwaty F. Effect of behavioral stage-based nutrition education on management of osteodystrophy among hemodialysis patients, Lebanon. *Patient Educ Couns*. 2015;98(9):1116-22.
52. Weisbord SD, Mor MK, Green JA, Sevvick MA, Shields AM, Zhao X, et al. Comparison of symptom management strategies for pain, erectile dysfunction, and depression in patients receiving chronic hemodialysis: a cluster randomized effectiveness trial. *Clin J Am Soc Nephrol*. 2013;8(1):90-9.
53. Wileman V, Chilcot J, Armitage CJ, Farrington K, Wellsted DM, Norton S, et al. Evidence of improved fluid management in patients receiving haemodialysis following a self-affirmation theory-based intervention: A randomised controlled trial. *Psychol Health*. 2016;31(1):100-14.
54. Wileman V, Farrington K, Chilcot J, Norton S, Wellsted DM, Almond MK, et al. Evidence that self-affirmation improves phosphate control in hemodialysis patients: a pilot cluster randomized controlled trial. *Ann Behav Med*. 2014;48(2):275-81.